Skip to content Skip to footer

News

Close

Sartar received Orphan Drug Designation from the FDA

Meet us in LSX Congress 2023!

Sartar received Orphan Drug Designation in EU

January 5, 2023

Maria Lahtinen appointed as a Quality Director

Sartar is strengthening its board of directors

Sartar featured on RTL7

October 29, 2021

Sartar Therapeutics was selected to NOME mentoring program

September 20, 2021

Business Finland granted Sartar R&D Funding

August 20, 2021

Mikael Maksimow joins Sartar as a COO. Welcome!

Sartar’s therapy method featured in Drug Target Review

Sartar is hiring a Drug Development Director

November 11, 2020

The Board of Directors of Sartar Therapeutics has appointed Katja Ivanitskiy as the new CEO